GB2281204A - Sustained release morphine compositions - Google Patents
Sustained release morphine compositions Download PDFInfo
- Publication number
- GB2281204A GB2281204A GB9315467A GB9315467A GB2281204A GB 2281204 A GB2281204 A GB 2281204A GB 9315467 A GB9315467 A GB 9315467A GB 9315467 A GB9315467 A GB 9315467A GB 2281204 A GB2281204 A GB 2281204A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hours
- morphine
- test
- pharmaceutical composition
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title claims abstract description 54
- 229960005181 morphine Drugs 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 11
- 238000013268 sustained release Methods 0.000 title claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000008188 pellet Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 230000036470 plasma concentration Effects 0.000 claims abstract description 8
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 239000011147 inorganic material Substances 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 239000011368 organic material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000008172 hydrogenated vegetable oil Substances 0.000 abstract description 5
- 239000004359 castor oil Substances 0.000 abstract description 3
- 235000019438 castor oil Nutrition 0.000 abstract description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 description 11
- 229920001515 polyalkylene glycol Polymers 0.000 description 8
- 239000004925 Acrylic resin Substances 0.000 description 5
- 229920000178 Acrylic resin Polymers 0.000 description 5
- 229920003086 cellulose ether Polymers 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- -1 gums Polymers 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9315467A GB2281204A (en) | 1993-07-27 | 1993-07-27 | Sustained release morphine compositions |
| IL10994494A IL109944A (en) | 1993-07-01 | 1994-06-08 | Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms |
| SG1996009186A SG50706A1 (en) | 1993-07-01 | 1994-06-09 | Sustained release compositions and a method of preparing pharmaceutical compositions |
| ES94304144T ES2124372T5 (es) | 1993-07-01 | 1994-06-09 | Composiciones de liberacion sostenida que contienen morfina. |
| DK94304144T DK0636370T4 (da) | 1993-07-01 | 1994-06-09 | Depotpræparater indeholdende morfin |
| EP94304144A EP0636370B2 (en) | 1993-07-01 | 1994-06-09 | Sustained release compositions containing morphine |
| AT94304144T ATE172376T1 (de) | 1993-07-01 | 1994-06-09 | Morphinenthaltende arzneizusammensetzungen mit verzögerter wirkstoffabgabe |
| DE69414046T DE69414046T3 (de) | 1993-07-01 | 1994-06-09 | Morphinenthaltende Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe |
| SK763-94A SK280534B6 (sk) | 1993-07-01 | 1994-06-23 | Prostriedok s udržiavaným uvoľňovaním a spôsob jeh |
| CZ19941550A CZ287918B6 (cs) | 1993-07-01 | 1994-06-23 | Orálně podávaná jednotková dávková forma s řízeným uvolňováním a způsob její výroby |
| NZ260883A NZ260883A (en) | 1993-07-01 | 1994-06-29 | Oral sustained-release medicaments containing morphine |
| IN571MA1994 IN183742B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-07-27 | 1994-06-29 | |
| FI943141A FI114285B (fi) | 1993-07-01 | 1994-06-30 | Menetelmä hitaasti vapauttavan farmaseuttisen annosyksikkömuodon valmistamiseksi |
| PL94304062A PL179282B1 (pl) | 1993-07-01 | 1994-06-30 | Doustny preparat do spowolnionego uwalniania morfinyi sposób wytwarzania multiczastek o spowolnionym uwalnianiu morfiny PL PL PL PL |
| AU66105/94A AU6610594A (en) | 1991-12-24 | 1994-06-30 | Sustained release compositions and a method of preparing pharmaceutical compositions |
| NO942470A NO306449B1 (no) | 1993-07-01 | 1994-06-30 | Oralt administrerbart morfinpreparat for vedvarende frigiving samt fremstilling av multipartikler for bruk i preparatet |
| CA002127166A CA2127166C (en) | 1993-07-01 | 1994-06-30 | Sustained release morphine compositions and a method of preparation |
| JP15121994A JP3647897B2 (ja) | 1993-07-01 | 1994-07-01 | 徐放性単位剤形 |
| HU9402007A HU220075B (hu) | 1993-07-01 | 1994-07-01 | Hosszan tartó hatóanyag-leadású morfintartalmú gyógyszerkészítmények és eljárás ezek előállítására |
| KR1019940015740A KR100365572B1 (ko) | 1993-07-01 | 1994-07-01 | 서방성조성물및약학조성물의제조방법 |
| US08/843,571 US5879705A (en) | 1993-07-27 | 1997-04-18 | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| AU52995/98A AU722358B2 (en) | 1991-12-24 | 1998-02-06 | Sustained release compositions and a method of preparing pharmaceutical compositions |
| US09/264,399 US6143328A (en) | 1993-07-27 | 1999-03-08 | Sustained release compositions and a method of preparing pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9315467A GB2281204A (en) | 1993-07-27 | 1993-07-27 | Sustained release morphine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9315467D0 GB9315467D0 (en) | 1993-09-08 |
| GB2281204A true GB2281204A (en) | 1995-03-01 |
Family
ID=10739462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9315467A Withdrawn GB2281204A (en) | 1991-12-24 | 1993-07-27 | Sustained release morphine compositions |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2281204A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
| IN (1) | IN183742B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2284760B (en) * | 1993-11-23 | 1998-06-24 | Euro Celtique Sa | A method of preparing pharmaceutical compositions by melt pelletisation |
| US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| US5849240A (en) | 1993-11-23 | 1998-12-15 | Euro-Celtique, S.A. | Method of preparing sustained release pharmaceutical compositions |
| US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| US5958452A (en) | 1994-11-04 | 1999-09-28 | Euro-Celtique, S.A. | Extruded orally administrable opioid formulations |
| US6068855A (en) | 1994-11-03 | 2000-05-30 | Euro-Celtique S. A. | Pharmaceutical composition containing a fusible carrier and method for producing the same |
| WO2004045551A3 (en) * | 2002-11-15 | 2004-12-09 | Branded Products For The Futur | Pharmaceutical composition |
| US8557286B1 (en) | 1999-04-22 | 2013-10-15 | Euroceltique, S.A. | Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
| EP0108218A2 (en) * | 1982-10-08 | 1984-05-16 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility |
| EP0271193A2 (en) * | 1986-10-31 | 1988-06-15 | Euroceltique S.A. | Controlled release hydromorphone composition |
| EP0377518A2 (en) * | 1989-01-06 | 1990-07-11 | F.H. FAULDING & CO. LIMITED | Sustained release pharmaceutical composition |
| WO1992001446A1 (en) * | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
| WO1992002209A1 (fr) * | 1990-07-31 | 1992-02-20 | Aiache Jean Marc | Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee |
-
1993
- 1993-07-27 GB GB9315467A patent/GB2281204A/en not_active Withdrawn
-
1994
- 1994-06-29 IN IN571MA1994 patent/IN183742B/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
| EP0108218A2 (en) * | 1982-10-08 | 1984-05-16 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility |
| EP0271193A2 (en) * | 1986-10-31 | 1988-06-15 | Euroceltique S.A. | Controlled release hydromorphone composition |
| EP0377518A2 (en) * | 1989-01-06 | 1990-07-11 | F.H. FAULDING & CO. LIMITED | Sustained release pharmaceutical composition |
| WO1992001446A1 (en) * | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
| WO1992002209A1 (fr) * | 1990-07-31 | 1992-02-20 | Aiache Jean Marc | Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee |
Non-Patent Citations (2)
| Title |
|---|
| British National Formulary No.25 (March 1993) page 181-see MST Continus * |
| Curr.Ther.Res.47 pages 869-878 (1990) * |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849240A (en) | 1993-11-23 | 1998-12-15 | Euro-Celtique, S.A. | Method of preparing sustained release pharmaceutical compositions |
| US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| GB2284760B (en) * | 1993-11-23 | 1998-06-24 | Euro Celtique Sa | A method of preparing pharmaceutical compositions by melt pelletisation |
| US5965163A (en) | 1993-11-23 | 1999-10-12 | Euro-Celtique, S.A. | Substained release compositions and a method of preparing pharmaceutical compositions |
| US6162467A (en) | 1993-11-23 | 2000-12-19 | Euro-Celtique, S.A. | Sustained release compositions and a method of preparing pharmaceutical compositions |
| US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| US6068855A (en) | 1994-11-03 | 2000-05-30 | Euro-Celtique S. A. | Pharmaceutical composition containing a fusible carrier and method for producing the same |
| US6335033B2 (en) | 1994-11-04 | 2002-01-01 | Euro-Celtique, S.A. | Melt-extrusion multiparticulates |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US6261599B1 (en) | 1994-11-04 | 2001-07-17 | Euro-Celtique, S.A. | Melt-extruded orally administrable opioid formulations |
| US5958452A (en) | 1994-11-04 | 1999-09-28 | Euro-Celtique, S.A. | Extruded orally administrable opioid formulations |
| US6706281B2 (en) | 1994-11-04 | 2004-03-16 | Euro-Celtique, S.A. | Melt-extrusion multiparticulates |
| US6743442B2 (en) | 1994-11-04 | 2004-06-01 | Euro-Celtique, S.A. | Melt-extruded orally administrable opioid formulations |
| US7510727B2 (en) | 1994-11-04 | 2009-03-31 | Purdue Pharma L.P. | Melt-extrusion multiparticulates |
| US8557286B1 (en) | 1999-04-22 | 2013-10-15 | Euroceltique, S.A. | Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
| WO2004045551A3 (en) * | 2002-11-15 | 2004-12-09 | Branded Products For The Futur | Pharmaceutical composition |
| US7192966B2 (en) | 2002-11-15 | 2007-03-20 | Branded Products For The Future | Pharmaceutical composition |
| US7652026B2 (en) | 2002-11-15 | 2010-01-26 | Branded Products For The Future | Pharmaceutical composition |
| US7973048B2 (en) | 2002-11-15 | 2011-07-05 | Branded Products For The Future | Pharmaceutical composition |
| US8188108B2 (en) | 2002-11-15 | 2012-05-29 | Branded Products For The Future | Pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9315467D0 (en) | 1993-09-08 |
| IN183742B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2000-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8506998B2 (en) | Pharmaceutical formulation | |
| US4765990A (en) | Sustained-release nifedipine preparation | |
| AU722358B2 (en) | Sustained release compositions and a method of preparing pharmaceutical compositions | |
| US6143328A (en) | Sustained release compositions and a method of preparing pharmaceutical compositions | |
| DE69022876T3 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| US5051263A (en) | Controlled-release formulations | |
| US4990341A (en) | Controlled release hydromorphone composition | |
| DE60210828T2 (de) | Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| EP0324981B1 (en) | New galenic formulations with programmed release | |
| US5186943A (en) | Compressed-molded preparations | |
| NZ244564A (en) | Pharmaceutical composition for treating pain of chronic medical conditions comprising ibuprofen and codeine in a ratio range of 15-25:1 | |
| DE3610037A1 (de) | Nifedipinkombinationspraeparat | |
| IE880855L (en) | Slow-release pharmaceutical agent | |
| GB2284760A (en) | Sustained release morphine compositions | |
| WO1989002738A1 (en) | Sustained-release nifedipine formulation | |
| GB2281204A (en) | Sustained release morphine compositions | |
| EP0566393A1 (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
| US5726201A (en) | Gemfibrozil containing pharmaceutical compositions | |
| JPH0530810B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS625915A (ja) | 塩酸ジルチアゼム徐放性製剤及びその製法 | |
| GB2288117A (en) | Sustained release morphine | |
| GB2260081A (en) | Use of Ibuprofen/codeine mixtures in treatment of chronic pain | |
| BG62234B1 (bg) | Фармацевтични състави,съдържащи гемфиброзил |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |